Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. April 2026 10:00 ET | Quelle: Folia Health

Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP

Folia Health launched a first of it's kind study with argenx to understand the real-world CIDP experience for patients and caregivers.
07. April 2026 08:00 ET | Quelle: FIRST ONSITE

First Onsite launches Life Sciences Division to protect critical environments

KELLIE MATZINGER, MICROBIOLOGY AND STERILIZATION AUTHORITY, LEADS FIRST ONSITE’S NEW LIFE SCIENCES DIVISION. GREENWOOD VILLAGE, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- First Onsite Property...
07. April 2026 07:00 ET | Quelle: MediWound Ltd.

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...
07. April 2026 01:00 ET | Quelle: Sanofi Winthrop Industrie

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale

Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires
07. April 2026 01:00 ET | Quelle: Sanofi Winthrop Industrie

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
02. April 2026 15:26 ET | Quelle: MediWound Ltd.

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
02. April 2026 11:58 ET | Quelle: Research and Markets

Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, including...
31. März 2026 17:23 ET | Quelle: BCC Research LLC

Global Ion Exchange Materials Market to Reach $5.9 Billion by 2030, Driven by Green Hydrogen, Water Treatment Standards and Energy Security Demands

The study highlights expanding applications in water treatment, pharmaceuticals, and chemical processing as key drivers of global market growth.
25. März 2026 12:15 ET | Quelle: Io Therapeutics, Inc.

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

The Io Therapeutics, Inc. clinical stage anti-cancer RXR agonist compound demonstrated efficacy in models of human multiple myeloma.
25. März 2026 11:10 ET | Quelle: GH Research PLC

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is...

Nächste Seite